Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients

Clinical Pharmacokinetics

Volumn 52, Issue 7, 2013, Pages 543-553

  Moltó, José ^a,b   Xinarianos, George ^c   Miranda, Cristina ^a   Pushpakom, Sudeep ^c   Cedeño, Samandhy ^a   Clotet, Bonaventura ^a,b   Owen, Andrew ^c   Valle, Marta ^b,d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; OROSOMUCOID; RALTEGRAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; FIRST PASS EFFECT; GENE FREQUENCY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PHARMACOGENETICS; PHARMACOKINETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; RITONAVIR; SULFONAMIDES;

EID: 84879624358     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-013-0057-6     Document Type: Article

References (25)

1. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568):1169-78.
2. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23(13):1679-88.
3. Rittweger M, Arastéh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet. 2007;46(9):739-56.
4. King JR, Wynn H, Brundage R, et al. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet. 2004;43(5):291-310.
5. Autar RS, Boffito M, Hassink E, et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother. 2005;56(5):908-13.
6. Avihingsanon A, van der Lugt J, Kerr SJ, et al. A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults. Clin Pharmacol Ther. 2009;85(4):402-8.
7. Schipani A, Egan D, Dickinson L, et al. Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. Antivir Ther. 2012;17(5):861-8.
8. Lubomirov R, di Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics. 2010;20(4):217-30.
9. Schipani A, Siccardi M, D'Avolio A, et al. Population pharmacokinetic modeling of the association between 63396C→T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother. 2010;54(12):5242-50.
10. Janneh O, Jones E, Chandler B, et al. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2007;60(5):987-93.
11. Janneh O, Owen A, Chandler B, et al. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS. 2005;19(18):2097-102.
12. Su Y, Zhang X, Sinko PJ. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004;1(1):49-56.
13. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics. 2010;20(2):112-20.
14. Droste JA, Aarnoutse RE, Koopmans PP, et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003;32(3):287-91.
15. Beal SL, Sheiner LB. NONMEM Users Guides. Ellicott City: Icon Development Solutions; 1989-1998.
16. Karlsson MO, Jonsson EN, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26(2):207-46.
17. Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
18. Moltó J, Barbanoj MJ, Miranda C, et al. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clin Pharmacokinet. 2008;47(10):681-92.
19. Sale M, Sadler BM, Stein DS. Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir. Antimicrob Agents Chemother. 2002;46(3):746-54.
20. Lu JF, Blaschke TF, Flexner C, et al. Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration. Drug Metab Dispos. 2002;30(12):1455-61.
21. Kappelhoff BS, Huitema AD, Crommentuyn KM, et al. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients. Br J Clin Pharmacol. 2005;59(2):174-82.
22. Vis P, Sekar V, van Schaick E, et al. Development and application of a population pharmacokinetic model of TMC114 in healthy volunteers and HIV-1 infected subjects alter administration of TMC114 in combination with low dose ritonavir [abstract no. 964] 15th meeting of the Population Approach Group in Europe. 2006 June 14-16; Bruges, Belgium.
23. Huber RD, Gao B, Sidler Pfändler MA, et al. Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol. 2007;292(2):C795-806.
24. Janneh O, Chandler B, Hartkoorn R, et al. Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother. 2009;64(5):1002-7.
25. Siccardi M, D'Avolio A, Baietto L, et al. SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV infected patients. J Int AIDS Soc. 2010;13(Suppl 4):P178.